Premium
Use of 5‐Fluorouracil Loaded Micelles and Cisplatin in Thermosensitive Chitosan Hydrogel as an Efficient Therapy against Colorectal Peritoneal Carcinomatosis
Author(s) -
Yun Qin,
Wang Si Song,
Xu Shan,
Yang Jin Ping,
Fan Juan,
Yang Ling Lin,
Chen Yue,
Fu Shao Zhi,
Wu Jing Bo
Publication year - 2017
Publication title -
macromolecular bioscience
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.924
H-Index - 105
eISSN - 1616-5195
pISSN - 1616-5187
DOI - 10.1002/mabi.201600262
Subject(s) - cisplatin , metastasis , drug delivery , colorectal cancer , self healing hydrogels , h&e stain , drug , fluorouracil , medicine , cancer research , pharmacology , micelle , chitosan , chemistry , chemotherapy , immunohistochemistry , pathology , cancer , biochemistry , organic chemistry , aqueous solution
Colorectal peritoneal carcinomatosis (CRPC) is a common systemic metastasis of intra‐abdominal cancers. Intraperitoneal chemotherapy against CRPC is at present the preferred treatment. The aim of this study is to develop a novel hydrogel drug delivery system through the combination of 5‐fluorouracil (5‐FU) loaded polymeric micelles and cisplatin (DDP) in biodegradable thermosensitive chitosan (CS) hydrogel. The prepared CS hydrogel drug is a free‐flowing solution at room temperature and forms a stationary gel at body temperature. Therefore, a CRPC mouse model is established to investigate the antitumor activity of CS hydrogel drug system. The results suggest that intraperitoneal administration of CS hydrogel drug can inhibit tumor growth and metastasis, and prolong survival time compared with other groups, thus improving the chemotherapeutic effect. Ki‐67 immunohistochemical analysis reveals that tumors in the CS hydrogel drug group has lower cell proliferation in contrast to other groups ( P < 0.001). Furthermore, hematoxylin‐eosin staining of liver and lung tissue indicates that the CS hydrogel drug has also a certain inhibitory effect on colorectal cancer metastasis to the liver and lung. Hence, the work highlights the potential clinical applications of the CS hydrogel drug.